E li Lilly CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in ...

Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

The Government and pharmaceutical giant Eli Lilly, the creator of weight loss drug Mounjaro, are teaming up to explore and ...

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...